Shield Therapeutics (LON:STX) Earns "Buy" Rating from Peel Hunt

Key Points

• Peel Hunt has reissued a "buy" rating for Shield Therapeutics (LON:STX) with a price objective of GBX 15, indicating a potential upside of 89.87% from its current price.
• As of Wednesday, Shield Therapeutics shares traded at GBX 7.90, showing a significant increase from the one-year low of GBX 2.10.
• The company is focused on delivering its product Accrufer®/Feraccru® to address iron deficiency, highlighting its role as a commercial-stage specialty pharmaceutical company.

Shield Therapeutics (LON:STX - Get Free Report)'s stock had its "buy" rating reissued by analysts at Peel Hunt in a research note issued to investors on Wednesday,Digital Look reports. They presently have a GBX 15 price objective on the stock. Peel Hunt's price objective would indicate a potential upside of 89.87% from the company's current price.

Shield Therapeutics Price Performance

Shares of Shield Therapeutics stock traded up GBX 0.55 on Wednesday, reaching GBX 7.90. 3,004,398 shares of the stock were exchanged, compared to its average volume of 2,827,746. The firm's 50 day moving average is GBX 6.55 and its 200-day moving average is GBX 4.03. Shield Therapeutics has a one year low of GBX 2.10 and a one year high of GBX 9.10. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The firm has a market cap of £82.29 million, a PE ratio of -395.00 and a beta of 1.42.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.